Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat and Decitabine in High Risk Acute Myeloid Leukemia
NCT03009240Phase 1Completed
- Sponsor
- City of Hope
- Start
- Aug 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Incidence of adverse effect up to 2 years, Dose limiting toxicities up to 28 days and 1 more. Started Aug 2017; status: completed.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03009240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009240.